Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 272

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 272
---
 with an introductory meeting to explore mutual interests, followed by the execution of a non -disclosureagreement on February3, 2022. Subsequently, APx engaged in multiple discussions and meetings involving senior executives, including then Chief Executive Officer Dan Braatz, Chief Financial Officer Xavier Martinez and director Alfredo Vara, as well as legal and financial advisors, to conduct due diligence on IB. Despite these efforts, IB informed APx on August18, 2022, that it would not proceed further due to prevailing macroeconomic conditions. During this period, APx and its Sponsor concurrently explored additional business combination opportunities. • Other Engagements: APx also engaged in discussions with various other entities in pursuit of a suitable business combination. However, these interactions did significantly progressor result in material negotiations. On September 28, 2022, BofA, the underwriter of APx’s IPO, delivered to APx a notice waiving its entitlement to the payment of its deferred underwriting fee with respect to the Business Combination with the Company, declining to serve in any capacity in connection with the Business Combination with the Company, confirming that it does not have any role with respect to the Business Combination with the Company and disclaiming any responsibility for any portion of this proxy statement/prospectus. On November 11, 2022, Mr. Bransfield was introduced to Mr. Calmet, the Chief Executive Officer of Heritas Argentina, by Mr. Trucco, a director of Bioceres Group PLC, to begin conversations regarding the future of Heritas Argentina as an affiliate of Bioceres, as Mr. Bransfield had successfully executed business combination transactions in the past. Mr. Bransfield served as director and Chief Executive Officer of Union Acquisition Corp, and Union Acquisition Corp. II, leading the companies through successful mergers with Bioceres Crop Solutions (NASDAQ: BIOX) and Procaps Group (NASDAQ: PROC) in March 2019 and September 2021, respectively. Mr. Bransfield previously served on the board of Procaps Group and sat on the audit committee and the mergers and acquisitions committee. Following Lightjump Acquisition Corp’s successful business combination with Moolec Science Ltd. (NASDAQ: MLEC) in December 2022, Mr. Bransfield now serves as a board member on its compensation and audit committees. On November 16, 2022, Messrs. Bransfield and Calmet met through a video call to discuss the possibility of creating a new